The T-cell engager field is advancing faster than ever. With multiple clinical approvals validating the staying power of this modality, and a new wave of next-generation solid tumor and autoimmune programs moving rapidly towards the clinic, the momentum behind T-Cell engagers has never been stronger. These therapies are increasingly cited as one of the most promising drivers of the next era of immunotherapy.
Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology and autoimmune disease.
Moving from Boston to San Diego for 2026, the 8th T-Cell Engager Therapeutics Summit stands as the industry’s most comprehensive end-to-end meeting dedicated to advancing, optimizing and translating T-cell engagers.
This case-study driven forum is designed to equip engineering, discovery, R&D, translational and clinical development teams with the actionable insights needed to engineer safer, more potent, durable and precisely targets TCEs for solid tumors, while also spotlighting the breakthroughs extending engager biology into autoimmune and inflammatory diseases.
If accelerating your TCE pipeline is a priority, this is a meeting you cannot afford to miss.
Over the past year, the sector has experienced a surge of investment, deal-making and strategic collaboration. Landmark partnerships such as BMS x JanuX Therapeutics, Candid Therapeutics x WuXi Biologics and AbbVie x EvolveImmune signal growing confidence in the transformative potential of immune-redirecting platforms and reinforce commitment to advancing TCE innovation across oncology and autoimmune disease.
Moving from Boston to San Diego for 2026, the 8th T-Cell Engager Therapeutics Summit stands as the industry’s most comprehensive end-to-end meeting dedicated to advancing, optimizing and translating T-cell engagers.
This case-study driven forum is designed to equip engineering, discovery, R&D, translational and clinical development teams with the actionable insights needed to engineer safer, more potent, durable and precisely targets TCEs for solid tumors, while also spotlighting the breakthroughs extending engager biology into autoimmune and inflammatory diseases.
If accelerating your TCE pipeline is a priority, this is a meeting you cannot afford to miss.
